Silence Therapeutics prices $175M offering to extend siRNA cash runway

Silence Therapeutics priced an upsized $175 million public offering of 12,962,963 American Depositary Shares at $13.50 per ADS, extending the clinical-stage biotech's cash runway for its short interfering RNA pipeline targeting rare and common diseases.

The London-based company said the offering will support development of its mRNAi GOLD platform, which uses proprietary chemistry to create siRNA therapies that precisely target and silence disease-causing genes. Each ADS represents three ordinary shares of £0.05 each in the company's capital.

The company granted underwriters a 30-day option to purchase up to an additional 1,944,444 ADSs at the offering price, less underwriting discounts and commissions. Jefferies, Morgan Stanley, Cantor and William Blair are acting as joint book-running managers for the offering.

The offering, expected to close on or about Aug. 13, follows a shelf registration statement declared effective by the SEC on May 27. The upsized deal reflects strong institutional demand for RNA interference therapeutics, a field where Alnylam Pharmaceuticals has established commercial products including Onpattro and Amvuttra, and Arrowhead Pharmaceuticals is advancing its own pipeline of RNAi candidates.

Silence Therapeutics develops precision-engineered siRNA therapies designed to silence disease-causing genes at the messenger RNA level. The mRNAi GOLD platform incorporates proprietary chemical modifications that enhance the potency, durability and tissue-targeting of siRNA molecules, a mechanism distinct from traditional small-molecule drugs and antibody therapies that target proteins after they are produced.

The company is advancing a growing pipeline of product candidates across cardiovascular, rare and common disease indications where existing treatments are limited or inadequate. The capital raise extends the company's cash runway as it moves candidates through clinical development, a critical factor for a clinical-stage biotech that generates no product revenue.

The $13.50 per ADS pricing represents a standard discount to recent trading levels for underwritten offerings. The upsizing from the originally announced deal size suggests institutional demand exceeded initial expectations, a positive signal for the company's clinical programs and the broader siRNA sector.

For existing shareholders, the offering introduces dilution of approximately 12.96 million ADSs, equivalent to roughly 38.9 million ordinary shares. The company's ability to raise capital at scale reflects continued investor confidence in the siRNA modality, which has gained commercial validation through Alnylam's approved products and a growing body of clinical evidence supporting RNA interference as a therapeutic approach.

The offering is being made through a prospectus supplement and accompanying prospectus filed with the SEC. The company's next clinical data readouts will determine whether the additional capital translates into pipeline value and ultimately shareholder returns. Investors will be watching for updates on the company's lead candidates as they progress through clinical trials.

This article is for informational purposes only and does not constitute investment advice.